The global personalized nutrition market size is calculated at USD 17.9 billion in 2025 and is forecasted to reach around USD 60.94 billion by 2034, accelerating at a CAGR of 14.63% from 2025 to 2034. The North America personalized nutrition market size surpassed USD 6.69 billion in 2024 and is expanding at a CAGR of 14.76% during the forecast period. The market sizing and forecasts are revenue-based (USD Million/Billion), with 2024 as the base year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Personalized Nutrition Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Personalized Nutrition Market, by Product
8.1.1. Active Measurement
8.1.1.1. Market Revenue and Forecast
8.1.2. Standard Measurement
8.1.2.1. Market Revenue and Forecast
9.1. Personalized Nutrition Market, by Application
9.1.1. Standard Supplement
9.1.1.1. Market Revenue and Forecast
9.1.2. Disease-based
9.1.2.1. Market Revenue and Forecast
10.1. Personalized Nutrition Market, by End use
10.1.1. Direct-to-consumer
10.1.1.1. Market Revenue and Forecast
10.1.2. Wellness & Fitness Centers
10.1.2.1. Market Revenue and Forecast
10.1.3. Hospital & Clinics
10.1.3.1. Market Revenue and Forecast
10.1.4. Institutions
10.1.4.1. Market Revenue and Forecast
10.1.5. Food Delivery Services
10.1.5.1. Market Revenue and Forecast
11.1. Personalized Nutrition Market, by Dosage Forms
11.1.1. Tablets
11.1.1.1. Market Revenue and Forecast
11.1.2. Capsule
11.1.2.1. Market Revenue and Forecast
11.1.3. Powders
11.1.3.1. Market Revenue and Forecast
11.1.4. Liquids
11.1.4.1. Market Revenue and Forecast
11.1.5. Others
11.1.5.1. Market Revenue and Forecast
12.1. Personalized Nutrition Market, by Disease
12.1.1. Customized to the needs of consumer
12.1.1.1. Market Revenue and Forecast
12.1.2. Fitness Goal Oriented Application
12.1.2.1. Market Revenue and Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product
13.1.2. Market Revenue and Forecast, by Application
13.1.3. Market Revenue and Forecast, by End use
13.1.4. Market Revenue and Forecast, by Dosage Forms
13.1.5. Market Revenue and Forecast, by Disease
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product
13.1.6.2. Market Revenue and Forecast, by Application
13.1.6.3. Market Revenue and Forecast, by End use
13.1.6.4. Market Revenue and Forecast, by Dosage Forms
13.1.7. Market Revenue and Forecast, by Disease
13.1.8. Rest of North America
13.1.8.1. Market Revenue and Forecast, by Product
13.1.8.2. Market Revenue and Forecast, by Application
13.1.8.3. Market Revenue and Forecast, by End use
13.1.8.4. Market Revenue and Forecast, by Dosage Forms
13.1.8.5. Market Revenue and Forecast, by Disease
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product
13.2.2. Market Revenue and Forecast, by Application
13.2.3. Market Revenue and Forecast, by End use
13.2.4. Market Revenue and Forecast, by Dosage Forms
13.2.5. Market Revenue and Forecast, by Disease
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product
13.2.6.2. Market Revenue and Forecast, by Application
13.2.6.3. Market Revenue and Forecast, by End use
13.2.7. Market Revenue and Forecast, by Dosage Forms
13.2.8. Market Revenue and Forecast, by Disease
13.2.9. Germany
13.2.9.1. Market Revenue and Forecast, by Product
13.2.9.2. Market Revenue and Forecast, by Application
13.2.9.3. Market Revenue and Forecast, by End use
13.2.10. Market Revenue and Forecast, by Dosage Forms
13.2.11. Market Revenue and Forecast, by Disease
13.2.12. France
13.2.12.1. Market Revenue and Forecast, by Product
13.2.12.2. Market Revenue and Forecast, by Application
13.2.12.3. Market Revenue and Forecast, by End use
13.2.12.4. Market Revenue and Forecast, by Dosage Forms
13.2.13. Market Revenue and Forecast, by Disease
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Forecast, by Product
13.2.14.2. Market Revenue and Forecast, by Application
13.2.14.3. Market Revenue and Forecast, by End use
13.2.14.4. Market Revenue and Forecast, by Dosage Forms
13.2.15. Market Revenue and Forecast, by Disease
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product
13.3.2. Market Revenue and Forecast, by Application
13.3.3. Market Revenue and Forecast, by End use
13.3.4. Market Revenue and Forecast, by Dosage Forms
13.3.5. Market Revenue and Forecast, by Disease
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product
13.3.6.2. Market Revenue and Forecast, by Application
13.3.6.3. Market Revenue and Forecast, by End use
13.3.6.4. Market Revenue and Forecast, by Dosage Forms
13.3.7. Market Revenue and Forecast, by Disease
13.3.8. China
13.3.8.1. Market Revenue and Forecast, by Product
13.3.8.2. Market Revenue and Forecast, by Application
13.3.8.3. Market Revenue and Forecast, by End use
13.3.8.4. Market Revenue and Forecast, by Dosage Forms
13.3.9. Market Revenue and Forecast, by Disease
13.3.10. Japan
13.3.10.1. Market Revenue and Forecast, by Product
13.3.10.2. Market Revenue and Forecast, by Application
13.3.10.3. Market Revenue and Forecast, by End use
13.3.10.4. Market Revenue and Forecast, by Dosage Forms
13.3.10.5. Market Revenue and Forecast, by Disease
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Forecast, by Product
13.3.11.2. Market Revenue and Forecast, by Application
13.3.11.3. Market Revenue and Forecast, by End use
13.3.11.4. Market Revenue and Forecast, by Dosage Forms
13.3.11.5. Market Revenue and Forecast, by Disease
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product
13.4.2. Market Revenue and Forecast, by Application
13.4.3. Market Revenue and Forecast, by End use
13.4.4. Market Revenue and Forecast, by Dosage Forms
13.4.5. Market Revenue and Forecast, by Disease
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product
13.4.6.2. Market Revenue and Forecast, by Application
13.4.6.3. Market Revenue and Forecast, by End use
13.4.6.4. Market Revenue and Forecast, by Dosage Forms
13.4.7. Market Revenue and Forecast, by Disease
13.4.8. North Africa
13.4.8.1. Market Revenue and Forecast, by Product
13.4.8.2. Market Revenue and Forecast, by Application
13.4.8.3. Market Revenue and Forecast, by End use
13.4.8.4. Market Revenue and Forecast, by Dosage Forms
13.4.9. Market Revenue and Forecast, by Disease
13.4.10. South Africa
13.4.10.1. Market Revenue and Forecast, by Product
13.4.10.2. Market Revenue and Forecast, by Application
13.4.10.3. Market Revenue and Forecast, by End use
13.4.10.4. Market Revenue and Forecast, by Dosage Forms
13.4.10.5. Market Revenue and Forecast, by Disease
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Forecast, by Product
13.4.11.2. Market Revenue and Forecast, by Application
13.4.11.3. Market Revenue and Forecast, by End use
13.4.11.4. Market Revenue and Forecast, by Dosage Forms
13.4.11.5. Market Revenue and Forecast, by Disease
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product
13.5.2. Market Revenue and Forecast, by Application
13.5.3. Market Revenue and Forecast, by End use
13.5.4. Market Revenue and Forecast, by Dosage Forms
13.5.5. Market Revenue and Forecast, by Disease
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product
13.5.6.2. Market Revenue and Forecast, by Application
13.5.6.3. Market Revenue and Forecast, by End use
13.5.6.4. Market Revenue and Forecast, by Dosage Forms
13.5.7. Market Revenue and Forecast, by Disease
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Forecast, by Product
13.5.8.2. Market Revenue and Forecast, by Application
13.5.8.3. Market Revenue and Forecast, by End use
13.5.8.4. Market Revenue and Forecast, by Dosage Forms
13.5.8.5. Market Revenue and Forecast, by Disease
14.1. DNA Fit
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Superior Supplement Manufacturing
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. Metagenetics, Inc.
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Asiamerica, Ingredients
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Nutralliance, Inc.
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Mixfix, Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Barrington Nutritionals
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Balchem Corporation
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Arizona Nutritional Supplements
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Maat Nutritionals
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
16.1. About Us
16.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample